Epigenetic Therapy for Epithelioid Sarcoma.
Cell
; 181(2): 211, 2020 04 16.
Article
en En
| MEDLINE
| ID: mdl-32302562
ABSTRACT
Tazemetostat is the first epigenetic therapy to gain FDA approval in a solid tumor. This lysine methyltransferase inhibitor targets EZH2, the enzymatic subunit of the PRC2 transcriptional silencing complex. Tumors with mutations in subunits of the SWI/SNF chromatin remodeling complex, inclusive of most epithelioid sarcomas, are sensitive to EZH2 inhibition.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Piridonas
/
Sarcoma
/
Benzamidas
/
Epigénesis Genética
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Año:
2020
Tipo del documento:
Article